NCT04065399 2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2 Recruiting
Clinical Trials
5 trialsNCT06229912 2026-02-19
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07356154 2026-01-21
A Study of Revumenib and Mezigdomide in People With Leukemia
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT05918913 2025-09-05
Expanded Access Program for Revumenib
Syndax Pharmaceuticals
No longer available
NCT06313437 2025-03-27
Revumenib in Combination With 7+3 + Midostaurin in AML
Dana-Farber Cancer Institute
Phase 1 Recruiting